Postępy Psychiatrii i Neurologii
eISSN: 2720-5371
ISSN: 1230-2813
Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
3/2025
vol. 34
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Artykuł przeglądowy

Stimulation of bed nucleus of the stria terminalis area for treatment-resistant obsessive-compulsive disorder and comorbid depressive and anxiety symptoms: a systematic literature review

Michał Sobstyl
1
,
Karol Karamon
2
,
Tadeusz Pietras
3
,
Kasper Sipowicz
4
,
Marcin Rylski
2

  1. Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland
  2. Department of Neuroradiology, Institute of Psychiatry and Neurology, Warsaw, Poland
  3. 2nd Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland
  4. Department of Interdisciplinary Disability Studies, The Maria Grzegorzewska University in Warsaw, Poland
Adv Psychiatry Neurol 2025; 34 (3): 177-188
Data publikacji online: 2025/08/26
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Purpose:
The bed nucleus of the stria terminalis (BNST) is a tiny nucleus connected by a bundle of axons with the amygdala. The BNST acts as a relay center, coordinating autonomic, limbic, behavioral, neuroendocrine, and motor functions. It plays a key role in anxiety and anxiety-related disorders. This review presents clinical outcomes of deep brain stimulation (DBS) of the BNST in treatment-resistant obsessive-compulsive disorder (trOCD) and treatment-resistant depression (TRD).

Views:
The medical literature search was conducted in MEDLINE and the Cochrane Central Register of Controlled Trials (CENTRAL). The identified studies were assessed on the basis of patient characteristics, clinical outcomes, and adverse events related to DBS. The reduction of the Y-OCBS in the reported studies ranged from 27% to 66%, with mean reduction of the YBOCS of 45% at a mean of 58 months. The authors of clinical studies also reported enhanced socio-occupational functioning and quality of life. Adverse effects included hypomania, depressive episodes, weight gain, emotional lability, and seizures. However, most side effects were transient and reversible with stimulation adjustments.

Conclusions:
Clinical experience with BNST DBS remains limited, with most studies treating trOCD and only two addressing TRD. Reported outcomes suggest reductions in obsessions, compulsions, and affective symptoms, alongside improved daily functioning. The BNST appears to be a promising DBS target for anxiety-related psychiatric disorders.

© 2025 Termedia Sp. z o.o.
Developed by Bentus.